2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 304

Anti-Citrullinated Protein Antibodies In Patients With Psoriatic Arthritis: Clinical Relevance
Abstract Number: 2916

Anti-Fibrillarin Antibodies Are Associated With More Severe Gastrointestinal Involvement and Poorer Survival
Abstract Number: 54

ANTI-Fibrotic and ANTI-Hypertrophic Effect Of Adipose Mesenchymal Stromal CELLS On Osteoarthritic Chondrocytes
Abstract Number: 2316

Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Abstract Number: 2385

Anti-IL-6 Antibody Clazakizumab Is More Potent Than Tocilizumab In Blocking In Vitro and Ex Vivo IL-6-Induced Functions
Abstract Number: 1279

Anti-IL-6 Receptor Antibody Is Effective In Arthritis Regardless Of Obesity In Mouse Model
Abstract Number: 2213

Anti-IL-6 Receptor Antibody Normalizes Both DKK-1 and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis
Abstract Number: 1504

Anti-Inflammation Effect Of Peroxisome Proliferator-Activated Receptor-ã (PPAR-ã) In Non-Obese Diabetic Mice With Sjogren’s Syndrome
Abstract Number: 1294

Anti-Inflammatory Effect Of Resveratrol As a Dietary Supplement In An Antigen-Induced Arthritis Rat Model
Abstract Number: 1286

Anti-Inflammatory Effects Of Tyrosine-Hydroxylase(TH)-Positive Catecholamine Producing Cells In Chronic Arthritis
Abstract Number: 1166

Anti-Inflammatory Property Of HDL In NOD1 Ligand Induced Kawasaki Arteritis In Mice
Abstract Number: 1613

Anti-Malarial Drugs (hydroxychloroquine and quinacrine) Decrease The Production Of Interferon-Alfa Initiated By TLR-9 Agonist
Abstract Number: 2513

Anti-Mullerian Hormone In Patients With Systemic Lupus Erythematosus
Abstract Number: 2546

Anti-Nucleosome Antibodies As a Predictor Factor For Relapses In Clinically Quiescent Systemic Lupus Erythematosus: Results Of a Prospective Cohort Study
Abstract Number: 2422

Anti-P. Gingivalis antibody Is Correlated With Severity Of Periodontitis But Not With Rheumatoid Arthritis Disease Activity In RA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].